Novel Fast and Reliable Method for Nano-Erythrosome Production Using Shear Force.
erythrocytes
extrusion
nanoerythrosomes
nanotechnology
new method
shear force
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
04
2020
accepted:
07
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
25
8
2021
Statut:
epublish
Résumé
The production of nano-erythrosomes (NEs) by extrusion, which is considered the "gold standard", has several disadvantages such as difficult equipment assembly, long procedure time, variable pressure, and problems with sterility. An alternative approach, using ultrasound probe, has been shown to overheat the sample and have suboptimal results compared to the extrusion method. In our study, we propose, develop, and test a new method for the fabrication of NEs based on shear force and then compare it to the "gold standard" extrusion approach. The new method consists of mechanical shear force disruption of the hemoglobin-depleted erythrocyte ghost membranes, with the aid of a rotor stator based tissue homogenizer. Using the same batches of erythrocyte ghost membranes, we compared NEs produced by shear force to NEs produced by the well-established extrusion approach. NEs were characterized for yield, size, encapsulation efficiency, morphology, and stability by flow cytometry (FC), transmission electron microscopy (TEM), and zeta potential analysis. The shear force based process was easier to set up, significantly faster, had better sterility control, and decreased variability between batches. The shear force method generated NEs with the desired size distribution (particles diameter ~125 nm), which were morphologically and functionally equivalent to the NEs produced by extrusion. NEs produced by shear force were stable in terms of counts, size, and fluorescence intensity for 3 weeks at +4°C. Moreover, they showed colloidal stability and minimal influence to centrifugal stress, turbulence shock, and hemolytic potential. The newly proposed shear force method allows faster, easier, and highly reproducible NEs production when compared to the conventional extrusion approach. The new setup allows simultaneous production of sterile batches of NEs, which have homogenous size distribution, good stability, and improved shelf life storage. The ability of the shear force method to process also high concentration samples indicates a future potential development of large-scale NEs production and industrial application, which has been a challenge for the extrusion method.
Identifiants
pubmed: 33149552
doi: 10.2147/DDDT.S258368
pii: 258368
pmc: PMC7604965
doi:
Substances chimiques
Drug Carriers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4547-4560Informations de copyright
© 2020 Capossela et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Control Release. 2007 Apr 2;118(2):145-60
pubmed: 17270305
Eur Cell Mater. 2014 Nov 25;28:372-86
pubmed: 25422948
Transfus Med Rev. 2017 Jan;31(1):26-35
pubmed: 27707522
Nanoscale Res Lett. 2017 Dec;12(1):202
pubmed: 28314369
Nat Commun. 2018 Jul 11;9(1):2684
pubmed: 29992966
Sci Rep. 2017 Mar 28;7:45521
pubmed: 28349962
Anticancer Res. 1994 May-Jun;14(3A):915-9
pubmed: 8074493
Materials (Basel). 2013 Aug 05;6(8):3294-3308
pubmed: 28811437
Biophys J. 2003 Aug;85(2):996-1004
pubmed: 12885646
Langmuir. 2007 Nov 6;23(23):11677-83
pubmed: 17939695
Int J Pharm. 2000 Mar 10;196(2):161-4
pubmed: 10699709
FASEB J. 2017 Feb;31(2):761-770
pubmed: 27836986
Methods Enzymol. 1987;149:221-9
pubmed: 3121983
Pharm Res. 2014 Jun;31(6):1553-65
pubmed: 24449438
Biophys J. 1998 Jun;74(6):2996-3002
pubmed: 9635753
Transfus Apher Sci. 2016 Dec;55(3):275-280
pubmed: 27856317
APL Bioeng. 2020 Apr 07;4(2):026103
pubmed: 32548539
Nano Today. 2015 Aug;10(4):487-510
pubmed: 26640510
PLoS One. 2016 Mar 22;11(3):e0152074
pubmed: 27003833
Adv Drug Deliv Rev. 2004 May 7;56(9):1257-72
pubmed: 15109768
Pharmacol Rep. 2012;64(5):1020-37
pubmed: 23238461
Blood Adv. 2018 Feb 13;2(3):165-176
pubmed: 29365311
Biomater Sci. 2016 Jul 21;4(7):1024-31
pubmed: 27090487
Sci Rep. 2018 Jan 25;8(1):1615
pubmed: 29371620
Expert Opin Drug Deliv. 2014 Mar;11(3):433-47
pubmed: 24456118
Curr Pharm Des. 2008;14(1):63-70
pubmed: 18220819
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
pubmed: 21690347
J Occup Med Toxicol. 2007 Dec 01;2:16
pubmed: 18053152
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):88-103
pubmed: 26941164
Drug Dev Ind Pharm. 2000 Dec;26(12):1247-57
pubmed: 11147125